
Release date: 2024-08-09 10:55:58 Article From: Lucius Laos Recommended: 231
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-small cell lung cancer (NSCLC) that has a specific EGFR gene mutation.
EXKIVITY can cause cardiac toxicity (including decreased ejection fraction, cardiomyopathy, and congestive heart failure) resulting in heart failure which can be fatal. In the pooled EXKIVITY safety population, heart failure occurred in 2.7% of patients including 1.2% Grade 3 reactions, 0.4% Grade 4 reactions, and one (0.4%) fatal case of heart failure.
The clinical manifestatioEXKIVITY can cause clinical manifestations of cardiotoxicityns of cardiotoxicity are diverse, including the following:
Heart failure is one of the more severe manifestations of cardiotoxicity, and patients may experience symptoms such as dyspnea, shortness of breath, and edema, which is caused by the heart's weakened pumping function to meet the body's demand for blood and oxygen.
Cardiac toxicity may cause arrhythmias, including tachycardia, bradycardia, ventricular tachycardia, atrial fibrillation, etc., which can disrupt the normal rhythm of the heart and affect the heart's effective pumping function.
EXKIVITY (moboxantinib), as a targeted therapy drug, may cause a series of cardiotoxic reactions while treating cancers such as non-small cell lung cancer. The following measures should be taken to address these cardiotoxins:
Depending on the patient's specific condition and the severity of cardiotoxicity, the doctor may recommend adjusting the dose of EXKIVITY.
If patients experience severe cardiotoxicity during treatment, such as heart failure, significantly reduced ejection fraction or severe arrhythmias, the drug should be discontinued immediately and treated accordingly.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3652024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:792025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:892025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:922025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: